CARB-X Announces First Award Of 2018; Seeks Partners For Antibacterial Research 15/02/2018 William New CARB-X, the private-public partnership for research on antimicrobial resistance, today announced its first award of 2018, nearly $2 million for the development of a new class of antibiotics. Meanwhile, the group has announced it is seeking to partner with accelerator organisations to build its pipeline of early development research projects. It also announced a study that called for a new global approach and greater financial incentives for antibiotic research. Continue reading -> Trump Budget Would Slash Funding For Health, International Organisations 13/02/2018 William New The Trump administration this week proposed drastic cuts in funding for international activities including foreign policy and global health in 2019, while further building up military and big business activities. Programs related to international activities will have to prove their value to American interests and other countries are demanded to pay more, according to the proposed budget sent yesterday to Congress, which is ultimately expected to set about the task of restoring numerous programs. Continue reading -> A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 William New The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries. Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts
Trump Budget Would Slash Funding For Health, International Organisations 13/02/2018 William New The Trump administration this week proposed drastic cuts in funding for international activities including foreign policy and global health in 2019, while further building up military and big business activities. Programs related to international activities will have to prove their value to American interests and other countries are demanded to pay more, according to the proposed budget sent yesterday to Congress, which is ultimately expected to set about the task of restoring numerous programs. Continue reading -> A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 William New The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries. Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts
A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 William New The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries. Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts
G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts
Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts
US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts
Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts
Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts
WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Posts navigation Older postsNewer posts